Stifel analyst Paul Matteis downgraded Biogen (NASDAQ: BIIB) from Buy to Hold with a price target of $89.00.The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE